Literature DB >> 20846684

Initial atypical diagnosis with carcinoma on subsequent prostate needle biopsy: findings at radical prostatectomy.

Ying-bei Chen1, Phillip M Pierorazio, Jonathan I Epstein.   

Abstract

PURPOSE: Limited data exist on radical prostatectomy findings performed for cancer on repeat biopsy following an initial atypical biopsy (atypical glands suspicious but not diagnostic for carcinoma).
MATERIALS AND METHODS: We compared 169 such men to 15,810 without an initial diagnosis of atypical glands suspicious for carcinoma who underwent radical prostatectomy from 1993 to 2008.
RESULTS: Median time between atypical biopsy and repeat biopsy showing cancer was 6.1 months (range 0.7 to 94.8). An initial diagnosis of atypical glands suspicious but not diagnostic for carcinoma correlated significantly with nonpalpable disease, biopsy Gleason score 6 and lower tumor volume on needle cores. Compared to radical prostatectomy without prior atypical findings, radical prostatectomy cases with an initial atypical biopsy had a significantly lower Gleason score (p <0.0001) and pathological stage (p = 0.001), with 126 (74.5%) Gleason score 6 and 140 (83.0%) organ confined. Only 2 (1.2%) cases showed seminal vesicle involvement and none had lymph node metastases. In addition to known preoperative parameters (clinical stage and biopsy Gleason score), the presence of initial atypical biopsy was an independent predictor of organ confined disease at radical prostatectomy. However, when tumor volume on needle biopsy was included in the multivariate analysis a diagnosis of atypical glands suspicious but not diagnostic for carcinoma lost its independent predictive value.
CONCLUSIONS: Prostate cancer diagnosed on needle biopsy following a diagnosis of atypical glands suspicious but not diagnostic of carcinoma demonstrates a significantly lower tumor grade and pathological stage at radical prostatectomy than cancer without such a diagnosis. Correlating with lower tumor volume on biopsy, the presence of initial atypical biopsy predicts organ confined disease at radical prostatectomy. However, a few cases with high Gleason score and advanced pathological stage in this group emphasize the importance of re-biopsy within 3 to 6 months following such a diagnosis.
Copyright © 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20846684     DOI: 10.1016/j.juro.2010.06.139

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  4 in total

Review 1.  Managing high-grade prostatic intraepithelial neoplasia (HGPIN) and atypical glands on prostate biopsy.

Authors:  Jeffrey J Tosoian; Ridwan Alam; Mark W Ball; H Ballentine Carter; Jonathan I Epstein
Journal:  Nat Rev Urol       Date:  2017-08-31       Impact factor: 14.432

2.  Rate of Gleason 7 or higher prostate cancer on repeat biopsy after a diagnosis of atypical small acinar proliferation.

Authors:  C Warlick; K Feia; J Tomasini; C Iwamoto; B Lindgren; M Risk
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-04-21       Impact factor: 5.554

Review 3.  Atypical small acinar proliferation (ASAP): Is a repeat biopsy necessary ASAP? A multi-institutional review.

Authors:  A Leone; B Gershman; K Rotker; C Butler; J Fantasia; A Miller; A Afiadata; A Amin; A Zhou; Z Jiang; T Sebo; A Mega; S Schiff; G Pareek; D Golijanin; J Yates; R J Karnes; J Renzulli
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-11-17       Impact factor: 5.554

4.  Atypical small acinar proliferation and two or more cores of high-grade intraepithelial neoplasia on a previous prostate biopsy are significant predictors of cancer during a transperineal template-guided saturation biopsy aimed at sampling one core for each 1 mL of prostate volume.

Authors:  Yasushi Nakai; Nobumichi Tanaka; Makito Miyake; Shunta Hori; Yoshihiro Tatsumi; Yosuke Morizawa; Tomomi Fujii; Noboru Konishi; Kiyohide Fujimoto
Journal:  Res Rep Urol       Date:  2017-09-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.